Is metformin or a GLP-1 better for PCOS?

Key takeaways

Dr. Linda's take

Women come in having already framed this as a fight: which drug wins. I understand why, because that is how these medications get sold. But it is the wrong shape for the question.

The older option has been the quiet workhorse of PCOS care for decades. It is cheap, it is a pill, and it nudges several things in the right direction at once. The newer medications move the scale harder and faster, and they carry a different price and a different set of trade-offs. Neither one is a cure, and neither one is approved for PCOS in the first place.

So I do not answer "which is better" in the abstract. I answer "better for what, for whom, and at what cost." That is the honest version, and it is the version that actually helps you choose. Let me walk through the axes women actually weigh.

What are metformin and a GLP-1 actually doing in PCOS?

Start with the shared foundation. Weight loss is regarded as the first-line treatment for PCOS because it can improve androgen levels, menstrual cyclicity, and glucose metabolism. Both of these medications are, in different ways, attempts to help the metabolic engine underneath the syndrome.

The older drug is the one most women have heard of first. Metformin is widely used to manage type 2 diabetes and is commonly prescribed in PCOS to address insulin resistance and associated metabolic and reproductive disturbances. In non-pregnant women, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance.

The newer drugs are a more recent addition to PCOS care. GLP-1 receptor agonists have been used as monotherapy or in combination with metformin to manage obesity and insulin resistance associated with PCOS. You can read more about the mechanism in semaglutide and PCOS.

How do metformin and a GLP-1 compare at a glance?

Here is the shortened version, on the axes women bring up most.

| What women weigh | Metformin | The newer injectable |
|---|---|---|
| Weight | Modest effect, not a first-line weight tool | Larger drop in body weight in head-to-head trials |
| Testosterone and androgens | Helps shift androgen levels, especially with insulin resistance | Similar or slightly greater shift, depending on the study |
| Menstrual regularity | Often helps cycles become more regular | Often helps, especially alongside weight change |
| Cost and access | Low-cost generic pill taken by mouth | Costly branded injection, and access can be harder |
| Side effects | Nausea and diarrhea are common early on | Nausea and headache more common than the pill |
| Pregnancy | May be continued in pregnancy under a clinician's care | Must be stopped before a planned pregnancy |

Each row below is unpacked in its own section. A table flattens nuance, so treat it as a map, not a verdict.

Which one helps more with weight?

This is the clearest win for the newer drugs. Compared with metformin, GLP-1 receptor agonists were more effective at improving insulin sensitivity and reducing body mass index and abdominal girth in a meta-analysis of eight randomized trials in women with PCOS.

That fits what the older medication says about itself. Metformin is not effective as a first-line therapy for weight loss, ovulation induction, or treatment of clinical hyperandrogenic features including hirsutism or acne. In other words, if the number on the scale is the thing you most want to move, the injectable has the stronger track record, and the pill was never really built for that job.

But notice the phrase "for weight." Weight is one axis of many, and it is not automatically the one that matters most for you.

Which one does more for testosterone and periods?

Here the gap narrows, and the honest answer is that it is close.

In a separate meta-analysis of nine randomized trials in just over a thousand women, exenatide lowered total testosterone and raised sex hormone-binding globulin more than metformin did, and exenatide combined with metformin reduced the free androgen index. That is a point in the newer column.

But it is not the whole story. In the meta-analysis that informed the 2023 international PCOS guideline, no differences were found between exenatide and metformin for weight, hyperandrogenism, or metabolic outcomes, other than slightly lower fasting blood glucose with metformin. Two careful reviews, looking at overlapping questions, did not land in the same place. That is your signal that on hormones and cycles, this is not a blowout in either direction.

For periods specifically, both sides have real support. In non-pregnant women, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance. The newer option's effect on cycles tends to travel with the weight it moves.

What about side effects, cost, and access?

The side effect profiles rhyme but differ. In the eight-trial comparison, GLP-1 receptor agonists were associated with a higher incidence of nausea and headache than metformin, but there were no significant differences in other data. The older pill's own reputation is for stomach upset, especially in the first weeks. We go deeper on the day-to-day in the side effects to expect with these medications.

Then there is the part that no lab value captures. The older option is an inexpensive generic pill you take by mouth. The newer medications are branded injectables that are typically far more expensive and can be harder to get covered. For a chronic condition you may manage for years, that difference is not a footnote. It is often the deciding factor, and there is no shame in it being the deciding factor.

Which is the better choice if you might get pregnant?

This axis can outrank all the others, because PCOS and fertility are so tangled. We also touch the timing question in the acne and hair-growth guide.

The two medications point in opposite directions when pregnancy enters the picture. In pregnancy, metformin may reduce early pregnancy loss, miscarriage, and preterm birth, though findings for gestational diabetes and preeclampsia are inconsistent. The newer option is the opposite situation. The semaglutide label directs that the medication be discontinued when pregnancy is recognized, and discontinued at least 2 months before a planned pregnancy because of the long half-life of semaglutide.

There is also a middle path some trials explore. In a 16-week randomized trial in overweight and obese women with PCOS, those taking semaglutide plus metformin lost more weight on average than those on metformin alone (6.09 kg versus 2.25 kg) and later had a higher natural pregnancy rate (35% versus 15%). Read that carefully. It is a small, short study, and everyone switched to the pill alone before conceiving. It is a hint about sequencing, not a prescription.

So which is better for PCOS?

If I have to compress it: for moving weight and insulin resistance, the head-to-head evidence favors the newer drugs. For hormones and periods, the two are close. For cost, access, and pregnancy planning, the older pill often has the easier profile. Many women end up not choosing at all, because the two can be used together.

And the frame that should sit underneath all of it is simple. Neither semaglutide nor tirzepatide is approved by the FDA to treat PCOS. Everything above is off-label use of drugs approved for other things, which is legal and common and also a reason to decide slowly, with a clinician, rather than off an advertisement.

If you want a starting point for whether any of this fits your situation, our eligibility quiz is a reasonable first step. It is a starting point, not a plan.

The honest bottom line

There is no universal winner, and anyone who names one is skipping the question that matters. "Better" is a personal calculation: better for your weight goals, or your cycles, or your budget, or your pregnancy timeline, weighed against side effects you are willing to live with.

What I can tell you is that both of these have real, published support for parts of PCOS care, and that the parts do not fully overlap. You are allowed to pick the tool that fits the job you care about most. You are also allowed to change the answer later, because PCOS is a long relationship, not a single decision.

Frequently asked questions

Is a GLP-1 better than metformin for weight loss in PCOS?

For weight, the evidence leans toward the newer drugs. Compared with metformin, GLP-1 receptor agonists were more effective at improving insulin sensitivity and reducing body mass index and abdominal girth in a meta-analysis of eight randomized trials in women with PCOS. Metformin is not effective as a first-line therapy for weight loss, ovulation induction, or treatment of clinical hyperandrogenic features including hirsutism or acne.

Does metformin or a GLP-1 lower testosterone more?

It is close, and the reviews do not fully agree. In a separate meta-analysis of nine randomized trials in just over a thousand women, exenatide lowered total testosterone and raised sex hormone-binding globulin more than metformin did, and exenatide combined with metformin reduced the free androgen index. The picture is not one-sided. In the meta-analysis that informed the 2023 international PCOS guideline, no differences were found between exenatide and metformin for weight, hyperandrogenism, or metabolic outcomes, other than slightly lower fasting blood glucose with metformin.

Which is better for my periods?

Both have support. In non-pregnant women, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance. And weight loss is regarded as the first-line treatment for PCOS because it can improve androgen levels, menstrual cyclicity, and glucose metabolism.

Which one is safer if I want to get pregnant?

They differ sharply here. In pregnancy, metformin may reduce early pregnancy loss, miscarriage, and preterm birth, though findings for gestational diabetes and preeclampsia are inconsistent. The newer option runs the other way. The semaglutide label directs that the medication be discontinued when pregnancy is recognized, and discontinued at least 2 months before a planned pregnancy because of the long half-life of semaglutide. This is a timing conversation to have before starting anything.

Is either one actually approved for PCOS?

No. Neither semaglutide nor tirzepatide is approved by the FDA to treat PCOS. Metformin is widely used to manage type 2 diabetes and is commonly prescribed in PCOS to address insulin resistance and associated metabolic and reproductive disturbances. All of this is off-label prescribing, which is legal and common but worth discussing openly.

Can I take metformin and a GLP-1 together?

Some trials study exactly that. GLP-1 receptor agonists have been used as monotherapy or in combination with metformin to manage obesity and insulin resistance associated with PCOS. Whether a combination makes sense for you is a clinician's call, not a decision to make from an article.

References

1. Women's health (London, England) (2024). A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. PubMed PMID 38444070. https://pubmed.ncbi.nlm.nih.gov/38444070/ (Accessed 2026-07-18).
2. Diabetes, obesity & metabolism (2025). Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges. PubMed PMID 40329601. https://pubmed.ncbi.nlm.nih.gov/40329601/ (Accessed 2026-07-18).
3. Reproductive biomedicine online (2019). GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. PubMed PMID 31229399. https://pubmed.ncbi.nlm.nih.gov/31229399/ (Accessed 2026-07-18).
4. BMC endocrine disorders (2023). Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. PubMed PMID 37974132. https://pubmed.ncbi.nlm.nih.gov/37974132/ (Accessed 2026-07-18).
5. Obesity reviews : an official journal of the International Association for the Study of Obesity (2024). Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. PubMed PMID 38355887. https://pubmed.ncbi.nlm.nih.gov/38355887/ (Accessed 2026-07-18).
6. Reproductive biology and endocrinology : RB&E (2025). Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. PubMed PMID 40713699. https://pubmed.ncbi.nlm.nih.gov/40713699/ (Accessed 2026-07-18).
7. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-18).
8. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-18).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-18.*